Lyra pauses work on sinusitis drug; Pathos AI licenses a new asset
Plus, news about Convergent Therapeutics, Turnstone Biologics and Sonnet BioTherapeutics:
Lyra Therapeutics pauses development of chronic rhinosinusitis drug: The company
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.